Development of a fluorescence polarization bead-based coupled assay to target different activity/conformation states of a protein kinase

Journal of Biomolecular Screening

Volumn 9, Issue 4, 2004, Pages 309-321

  Lu, Zhuomei ^a   Yin, Zhizhang ^a   James, Linda ^a   Syto, Rosalinda ^a   Stafford, Jill M ^a   Koseoglu, Sandra ^a   Mayhood, Todd ^a   Myers, Joseph ^a   Windsor, William ^a   Kirschmeier, Paul ^a   Samatar, Ahmed A ^a   Malcolm, Bruce ^a   Turek Etienne, Tammy C ^a   Kumar, C Chandra ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Akt; High throughput screening; IMAP; Protein kinase inhibitors

Indexed keywords

3' PHOSPHATIDYLINOSITOL DEPENDENT KINASE 1; ADENOSINE TRIPHOSPHATE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHORUS 33; PROTEIN KINASE B BETA; PROTEIN KINASE C INHIBITOR; PROTEIN KINASE INHIBITOR; STAUROSPORINE; THREONINE; UNCLASSIFIED DRUG; 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE; 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE; AKT1 PROTEIN, HUMAN; AKT2 PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; RECOMBINANT PROTEIN;

ARTICLE; ASSAY; BINDING SITE; CONTROLLED STUDY; DRUG PROTEIN BINDING; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME CONFORMATION; ENZYME PHOSPHORYLATION; ENZYME SPECIFICITY; ENZYME SUBSTRATE; EVALUATION; FLUORESCENCE POLARIZATION; HIGH THROUGHPUT SCREENING; HUMAN; IC 50; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; VALIDATION PROCESS; CHEMISTRY; FLUORESCENCE POLARIZATION IMMUNOASSAY; GENETICS; IN VITRO STUDY; LIPID METABOLISM; METABOLISM; METHODOLOGY; PHOSPHORYLATION; PROTEIN CONFORMATION;

ADENOSINE TRIPHOSPHATE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMANS; LIPID METABOLISM; PHOSPHORYLATION; PROTEIN CONFORMATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECOMBINANT PROTEINS;

EID: 2442449561     PISSN: 10870571     EISSN: None     Source Type: Journal    
DOI: 10.1177/1087057104263506     Document Type: Article

References (29)

1. Cohen P: Protein kinases-the major drug targets of the twenty-first century? Nat Rev Drug Discovery 2002;1:309-315.
2. Dancey J, Sausville EA: Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discovery 2003;2:296-313.
3. Blume-Jensen P, Hunter T: Oncogenic kinase signalling. Nature 2001;411:355-365.
4. Kumar C, Madison V: Drugs targeted against protein kinases. Expert Opin Emerging Drugs 2001;6:303-315.
5. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S: The protein kinase complement of the human genome. Science 2002;298:1912-1934.
6. Gaudet E, Huang KS, Zhang Y, Huang W, Mark D, Sportsman JR: A homogeneous fluorescence polarization assay adaptable for a range of protein serine/ threonine and tyrosine kinases. J Biomol Screen 2003;8:164-175.
7. Turek T, Small EC, Bryant RW, Hill WAG: Development and validation of a competitive AKT serine/threonine kinase fluorescence polarization assay using a product-specific anti-phospho-serine antibody. Anal Biochem 2001;299:45-53.
8. Turek T, Kober TP, Stafford JM, Bryant RW: Development of a fluorescence polarization Akt serine/threonine kinase assay using an immobilized metal affinity-based technology. Assay Drug Dev Tech 2003;1:1-9.
9. Sportsman J, Lee SK, Diley H, Bukar R: Fluorescence polarization. In Delvin JP (ed), High Throughput Screening: The Discovery of Bioactive Substances. New York: Marcel Dekker, 1997:389-399.
10. Sportsman J, Daijo J, Gaudet EA: Fluorescence polarization assays in signal transduction discovery. Comb Chem High Throughput Screen 2003;6:195-200.
11. Huse M, Kuriyan J: The conformational plasticity of protein kinases. Cell 2002;109:275-282.
12. Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, Miller WT, et al: Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 2002;62:4236-4243.
13. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J: Structural mechanism for ST1-571 inhibition of abelson tyrosine kinase. Science 2000;289:1938-1942.
14. Pargellis C, Tong L, Churchill L, Cirillo PF, Gilmore T, Graham AG, et al: Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat Struct Biol 2002;4:268-272.
15. Druker B: Perspectives on the development of a molecularly targeted agent. Cancer Cell 2002;1:31-36.
16. Capdeville R, Buchdunger E, Zimmermann J, Matter A: Glivec (ST1571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discovery 2002;1:493-502.
17. Staal SP: Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci USA 1987;84:5034-5037.
18. Vivanco I, Sawyers CL: The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501.
19. Brazil D, Hemmings BA: Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem Sci 2001;26:657-664.
20. Lawlor M, Alessi DR: PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? J Cell Sci 2001;114:2903-2910.
21. Testa J, Bellacosa A: AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA 2001;98:10983-10985.
22. Scheid M, Woodgett JR: Unravelling the activation mechanism of protein kinase B/Akt. FEBS Lett 2003;27349:1-5.
23. Alessi D, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB, et al: Characterization of a 3′-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B-alpha. Curr Biol 1997;7:261-269.
24. Lawlor M, Mora A, Ashby PR, Williams MR, Murray-Tait V, Malone L, et al: Essential role of PDK1 in regulating cell size and development in mice. Embo J 2002;21:3728-3738.
25. Kumar C, Diao R, Yin Z, Liu Y, Samatar AA, Madison V, et al: Expression, purification, characterization and homology modeling of active Akt/PKB, a key enzyme involved in cell survival signaling. Biochim Biophys Acta 2001;1526:257-268.
26. Alessi D, Cohen P: Mechanism of activation and function of protein kinase B. Curr Opin Genet Dev 1998;8:55-62.
27. Zhang J, Chung T, Oldenburg K: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biol Chem 1999;4:67-73.
28. Schindler T, Sicheri F, Pico A, Gazit A, Levitzki A, Kuriyan J: Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. Mol Cell 1999;5:639-648.
29. Xu W, Harrison SC, Eck MJ: Three-dimensional structure of the tyrosine kinase c-Src. Nature 1999;385:595-602.